Published in Br J Haematol on April 15, 2009
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med (2014) 6.89
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell (2010) 4.18
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia (2010) 4.09
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet (2011) 4.02
Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med (2014) 3.75
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell (2010) 3.46
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood (2012) 2.88
Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol (2011) 2.69
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood (2011) 2.52
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood (2011) 2.50
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood (2011) 2.47
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
The genetic basis of myelodysplasia and its clinical relevance. Blood (2013) 1.95
Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer (2010) 1.93
Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood (2009) 1.90
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood (2012) 1.85
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med (2013) 1.71
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol (2012) 1.56
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia (2013) 1.44
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia (2014) 1.41
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood (2013) 1.37
Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol (2011) 1.33
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica (2010) 1.32
Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica (2012) 1.31
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica (2011) 1.30
Myeloid malignancies: mutations, models and management. BMC Cancer (2012) 1.24
Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med (2015) 1.21
Functional and cancer genomics of ASXL family members. Br J Cancer (2013) 1.21
Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J (2014) 1.18
The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia (2010) 1.18
Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. Haematologica (2013) 1.17
Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest (2011) 1.16
Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica (2009) 1.14
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica (2012) 1.13
Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica (2013) 1.13
U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res (2014) 1.13
Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood (2013) 1.12
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. J Clin Invest (2013) 1.12
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood (2014) 1.10
Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am (2010) 1.08
Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Semin Oncol (2012) 1.03
Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J (2016) 1.02
Molecular biology of myelodysplastic syndromes. Semin Oncol (2011) 1.01
Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica (2010) 1.01
Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer J (2011) 1.01
Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes. Mol Cytogenet (2010) 1.00
Epigenetic regulation in cancer progression. Cell Biosci (2014) 0.99
TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PLoS One (2012) 0.98
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood (2015) 0.97
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest (2015) 0.96
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica (2015) 0.94
Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. Haematologica (2013) 0.91
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS. Leukemia (2014) 0.91
De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome. Hum Mol Genet (2015) 0.90
CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases. Mol Cell (2014) 0.90
Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res (2010) 0.90
Myelodysplastic syndromes. Clin Lab Med (2011) 0.90
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol (2012) 0.89
Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med Res Rev (2015) 0.88
Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. Expert Rev Hematol (2012) 0.88
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. Oncotarget (2015) 0.88
Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica (2013) 0.87
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. J Hematol Oncol (2014) 0.87
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial. Oncotarget (2014) 0.87
Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer J (2011) 0.86
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica (2015) 0.86
Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Haematologica (2012) 0.86
The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica (2011) 0.86
Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol Oncol Clin North Am (2012) 0.86
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study. PLoS One (2012) 0.85
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One (2014) 0.85
Alterations of 5-hydroxymethylcytosine in human cancers. Cancers (Basel) (2013) 0.85
Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing? Curr Hematol Malig Rep (2015) 0.85
Evi1 forms a bridge between the epigenetic machinery and signaling pathways. Oncotarget (2011) 0.84
Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research. Blood (2015) 0.84
Molecular biology of Philadelphia-negative myeloproliferative neoplasms. Rev Bras Hematol Hemoter (2012) 0.83
Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"? J Biomed Biotechnol (2011) 0.83
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. Exp Hematol Oncol (2015) 0.83
Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology. J Mol Diagn (2011) 0.83
Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS One (2012) 0.82
Perspectives and future directions for epigenetics in hematology. Blood (2013) 0.82
Molecular pathogenesis of AML: translating insights to the clinic. Best Pract Res Clin Haematol (2013) 0.81
Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. Oncotarget (2014) 0.81
Molecular genetics of myelofibrosis and its associated disease phenotypes. Transl Med UniSa (2014) 0.81
Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations. Haematologica (2014) 0.81
The role of chromatin modifiers in normal and malignant hematopoiesis. Blood (2013) 0.80
Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res (2014) 0.80
Next generation sequencing of acute myeloid leukemia: influencing prognosis. BMC Genomics (2015) 0.80
I walk the line: how to tell MDS from other bone marrow failure conditions. Curr Hematol Malig Rep (2014) 0.79
Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol (2015) 0.78
ASXL genes and RUNX1: an intimate connection? Blood (2014) 0.78
Transferase activity function and system development process are critical in cattle embryo development. Funct Integr Genomics (2010) 0.78
Epigenetic regulators and their impact on therapy in acute myeloid leukemia. Haematologica (2016) 0.78
The molecular basis of myeloid malignancies. Proc Jpn Acad Ser B Phys Biol Sci (2014) 0.78
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
International network of cancer genome projects. Nature (2010) 20.35
Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet (2007) 9.88
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA (2011) 4.84
Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res (2009) 4.47
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res (2006) 3.81
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
How basal are triple-negative breast cancers? Int J Cancer (2008) 3.18
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood (2010) 3.06
Functional proteomics mapping of a human signaling pathway. Genome Res (2004) 3.04
Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 2.96
Integrated profiling of basal and luminal breast cancers. Cancer Res (2007) 2.86
Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res (2006) 2.52
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood (2013) 2.42
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood (2008) 2.39
Wind in November, Q fever in December. Emerg Infect Dis (2004) 2.38
Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res (2005) 2.26
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood (2012) 2.23
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol (2011) 2.20
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica (2008) 2.15
Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol (2004) 2.11
Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene (2004) 2.09
Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood (2002) 2.06
Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res (2005) 2.05
A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat (2010) 2.03
Induction of T helper type 2 immunity by a point mutation in the LAT adaptor. Science (2002) 2.01
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood (2008) 1.98
Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res (2005) 1.96
DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med (2004) 1.96
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer (2010) 1.93
CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A (2011) 1.91
Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol (2002) 1.89
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood (2012) 1.88
Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat (2010) 1.81
Cancer stem cells in breast: current opinion and future challenges. Pathobiology (2008) 1.77
Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res (2006) 1.75
Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood (2008) 1.74
Junctional recruitment of mammalian Scribble relies on E-cadherin engagement. Oncogene (2005) 1.73
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol (2010) 1.71
High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol (2007) 1.70
Chromosome arm 8p and cancer: a fragile hypothesis. Lancet Oncol (2003) 1.70
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood (2012) 1.68
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood (2007) 1.67
Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther (2009) 1.66